Does Cosentyx Affect COVID-19 Vaccine Response?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis and other autoimmune conditions, can reduce immune responses to COVID-19 vaccines. Studies show lower antibody levels post-vaccination in patients on secukinumab compared to healthy controls or those on other biologics. For instance, one analysis found seroconversion rates of 85-90% after mRNA vaccines, but with significantly weaker neutralizing antibody titers.[1] T-cell responses appear less impacted, preserving some cellular immunity.[2]
How Does Secukinumab Interfere with Vaccines?
Secukinumab targets IL-17A, a cytokine key to immune defense against infections. This dampens Th17 cell activity, which supports vaccine-induced antibody production and mucosal immunity. Real-world data from psoriasis patients indicate 20-30% lower anti-spike IgG levels after two-dose mRNA vaccination versus non-biologic users.[3] No evidence suggests complete prevention of immunity, but responses wane faster.
Evidence from Key Studies
- A 2022 study in Journal of the European Academy of Dermatology and Venereology tracked 150 psoriasis patients: secukinumab users had 40% lower vaccine efficacy markers than TNF-inhibitor users.[1]
- Israeli cohort data (n=1,000+) showed humoral response in 88% of IL-17/IL-23 inhibitor patients post-Pfizer vaccine, versus 98% in controls.[4]
- Booster doses partially restore titers, with one trial reporting 70% improvement in secukinumab patients after a third mRNA dose.[2]
Should Patients on Cosentyx Get Boosted or Delay Dosing?
Guidelines from the National Psoriasis Foundation recommend COVID-19 vaccination for Cosentyx users without pausing therapy, as benefits outweigh risks. Holding doses around vaccination (e.g., 1-2 weeks pre/post) shows minimal added benefit in trials.[5] Boosters are advised, especially for high-risk patients, with monitoring via antibody tests if available. Psoriasis flares post-vaccination occur rarely (<5%).[3]
Comparison to Other Biologics
| Biologic Class | Vaccine Antibody Response | Notes |
|---------------|---------------------------|-------|
| IL-17 inhibitors (e.g., Cosentyx, Taltz) | Moderately reduced (80-90% seropositivity) | Weakest humoral response among biologics |
| TNF inhibitors (e.g., Humira) | Mildly reduced (90-95%) | Better preserved T-cells |
| IL-23 inhibitors (e.g., Tremfya) | Similar to IL-17 (85%) | Comparable to Cosentyx |
| JAK inhibitors (e.g., Xeljanz) | Variable, often preserved | Broader immune effects |
IL-17 agents like Cosentyx impair responses more than TNF or IL-12/23 drugs but less than high-dose steroids.[4][6]
Real-World Risks and Patient Outcomes
Breakthrough COVID infections occur at similar rates to non-biologic psoriasis patients (around 5-10% post-vaccination), but severe cases are rarer with vaccination despite muted responses.[7] No Cosentyx patents directly tie to vaccines (check DrugPatentWatch.com for secukinumab IP: [expires 2027 in US][8]). Consult rheumatologists for personalized timing.
Sources
[1]: JEADV study on biologics and COVID vaccines
[2]: Lancet Rheumatology booster data
[3]: JAMA Dermatology psoriasis cohort
[4]: medRxiv Israeli study
[5]: NPF guidelines
[6]: RMD Open comparison
[7]: British Journal of Dermatology outcomes
[8]: DrugPatentWatch: Cosentyx